Key statistics
On Friday, Roche Holding AG (RHHBY:QXI) closed at 37.61, -11.36% below its 52-week high of 42.43, set on Aug 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.64 |
---|---|
High | 37.76 |
Low | 37.44 |
Bid | -- |
Offer | -- |
Previous close | 38.17 |
Average volume | 911.06k |
---|---|
Shares outstanding | 6.47bn |
Free float | 331.63m |
P/E (TTM) | 19.91 |
Market cap | 246.59bn USD |
EPS (TTM) | 1.89 USD |
Annual div (ADY) | 1.35 USD |
---|---|
Annual div yield (ADY) | 3.59% |
Div ex-date | Mar 14 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of Nov 08 2024 21:08 GMT.
More ▼
- Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
- Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
- New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%
- Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
- FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
- Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
More ▼